Profile
Dr Simon Ong completed his MBBS training at the National University of Singapore in 1990. After completing a year of housemanship, 2 years of National Service and a year of rotation to Psychiatry and Neonatology, he enrolled into the SGH Internal Medicine Traineeship Program in 1994. Over the next 3 years, he completed Basic Specialty Training by rotating through all the internal medicine specialties in SGH and passing his membership examinations (MMed & MRCP) in 1997. Following which he was accepted into Advanced Specialty Training in Medical Oncology. He successfully exited in 2000 and did his fellowship in cancer pharmacology at the Sydney Cancer Center, Royal Prince Alfred Hospital from 2000 to 2012.
Education
- USMLE, Educational Commission for Foreign Medical Graduates (ECFMG)
- MRCP, Royal College of Physicians (UK)
- MMed (Int Med), National University of Singapore
- MBBS, National University of Singapore
View More +
Professional Appointments and Committee Memberships
- Member, Hospice Care Association
- Member, Dover Park Hospice
- Member, Singapore Society of Oncology
- Member, Royal College of Physician (UK)
View More +
Awards
- SingHealth Excellence Award 2016 – Outstanding Educator
- YLLSOM Special Recognition Award, Role Model to the Medicine Graduating Class of 2015
- Faculty Appreciation Award, Duke-NUS GMS, 2014
- Faculty Award – Most Inspiring, Duke-NUS GMS, 2014
- Outstanding Developer for Medical Oncology Elective, 2013
View More +
Publications
- Teo R, Goh BK, Tai DW, Allen JC, Lim TK, Hwang JS, Tan DM, Lee SY, Chan CY, Cheow PC, Chow PK, Ooi LL, Chung AY, Ong S. Validation and comparison between current prognostication systems for pancreatic neuroendocrine neoplasms: A single-institution experience with 176 patients. Surgery. 2017 Jan 19. pii: S0039-6060(16)30852-2. doi: 10.1016/j.surg.2016.12.001. [Epub ahead of print]
-
Liu Y, Chew MH, Tham CK, Tang CL, Ong SY, Zhao Y. Methylation of serum SST gene is an independent prognostic marker in colorectal cancer. Am J Cancer Res. 2016 Sep 1;6(9):2098-2108. eCollection 2016 Sep 1.
- Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol. 2016 Aug 23;3(1):e000095. doi: 10.1136/bmjgast-2016-000095. eCollection 2016 Aug 23.
- Wang J, Wang X, Zhao M, Choo SP, Ong SJ, Ong SY, Chong SS, Teo YY, Lee CG. Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. PLoS One. 2014 Nov 5;9(11):e111694. doi: 10.1371/journal.pone.0111694. eCollection 2014 Nov 5.
- Tham C, Chew M, Soong R, Lim J, Ang M, Tang C, Zhao Y, Ong SY, Liu Y. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
- Liu Y, Tham CK, Ong SY, Ho KS, Lim JF, Chew MH, Lim CK, Zhao Y, Tang CL, Eu KW. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study. Biomarkers. 2013 Aug;18(5):399-405. doi: 10.3109/1354750X.2013.798745.
- Farid M, Lee MJ, Chew MH, Ong WS, Sairi AN, Foo KF, Choo SP, Koo WH, Ong S, Koh PK, Quek R. Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities. Mol Clin Oncol. 2013 Jan;1(1):190-194. Epub 2012 Sep 19.
- Neo PS, Poon MC, Peh TY, Ong SY, Koo WH, Santoso U, Goh CR, Yee AC. Improvements in end-of-life care with a protocol-based pathway for cancer patients dying in a Singapore hospital. Ann Acad Med Singapore. 2012 Nov;41(11):483-93.
- Farid M, Chowbay B, Chen X, Tan SH, Ramasamy S, Koo WH, Toh HC, Choo SP, Ong SY. Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemother Pharmacol. 2012 Jul;70(1):141-50. doi: 10.1007/s00280-012-1895-x.
View More +
